E
Edward Doo
Researcher at National Institutes of Health
Publications - 61
Citations - 9442
Edward Doo is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Hepatitis B & Hepatitis B virus. The author has an hindex of 35, co-authored 60 publications receiving 8079 citations. Previous affiliations of Edward Doo include California Pacific Medical Center.
Papers
More filters
Journal ArticleDOI
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri,Rohit Loomba,Arun J. Sanyal,Joel E. Lavine,Mark L. Van Natta,Manal F. Abdelmalek,Naga Chalasani,Srinivasan Dasarathy,Anna Mae Diehl,Bilal Hameed,Kris V. Kowdley,Arthur J. McCullough,Norah A. Terrault,Jeanne M. Clark,James Tonascia,Elizabeth M. Brunt,David E. Kleiner,Edward Doo +17 more
TL;DR: Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification.
Journal ArticleDOI
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
Kittichai Promrat,Glen Lutchman,Gabriel I. Uwaifo,Renee J. Freedman,Alejandro Soza,Theo Heller,Edward Doo,Marc G. Ghany,Ahalya Premkumar,Yoon Park,T. Jake Liang,Jack A. Yanovski,David E. Kleiner,Jay H. Hoofnagle +13 more
TL;DR: It is indicated that treatment with an insulin‐sensitizing agent can lead to improvement in biochemical and histological features of NASH and support the role of insulin resistance in the pathogenesis of this disease.
Journal ArticleDOI
Acute liver failure: Summary of a workshop.
TL;DR: The outcome of ALF varies by etiology, favorable prognoses being found with acetaminophen overdose, hepatitis A, and ischemia, and poor prognosed with drug‐induced ALF, hepatitis B, and indeterminate cases, and excellent intensive care is critical in management of patients with ALF.
Management of hepatitis B: Summary of a clinical research workshop Potential conflict of interest: Dr. Lok is a consultant and received grants from GlaxoSmithKline, Bristol-Myers Squibb, Idenix, Gilead, Roche, and Innogenetics.
TL;DR: Several oral nucleoside analogues with activity against HBV have been shown to be effective in suppressing viral levels and improving biochemical and histological features of disease in a high proportion of patients with and without HBeAg, at least in the short term.
Journal ArticleDOI
Management of Hepatitis B: Summary of a Clinical Research Workshop
TL;DR: In this article, the hepatitis B virus (HBV) is caused by persistent infection with HBV, a unique DNA virus that replicates through an RNA intermediate produced from a stable covalently closed circular DNA molecule.